PRAMIPEXOLE AN pramipexole dihydrochloride monohydrate 1 mg tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pramipexole an pramipexole dihydrochloride monohydrate 1 mg tablet blister pack

southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate -

SIMIPEX pramipexole dihydrochloride monohydrate 1 mg tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

simipex pramipexole dihydrochloride monohydrate 1 mg tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.,the symptomatic treatment of primary restless legs syndrome.

SIMPRAL pramipexole dihydrochloride monohydrate 1 mg tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

simpral pramipexole dihydrochloride monohydrate 1 mg tablet blister pack

alphapharm pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet - excipient ingredients: hyprolose; colloidal anhydrous silica; crospovidone; magnesium stearate; pregelatinised maize starch; sodium citrate; mannitol - simpral is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. it is also indicated for the symptomatic treatment of primary restless legs syndrome.

APO-PRAMIPEXOLE pramipexole dihydrochloride monohydrate 1 mg tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

apo-pramipexole pramipexole dihydrochloride monohydrate 1 mg tablet blister pack

southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. the symptomatic treatment of primary restless legs syndrome.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 3 mg modified release tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 3 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3 mg - tablet, modified release - excipient ingredients: silicon dioxide; calcium hydrogen phosphate; hypromellose; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 3.75 mg modified release tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 3.75 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3.75 mg - tablet, modified release - excipient ingredients: calcium hydrogen phosphate; hypromellose; silicon dioxide; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 0.375 mg modified release tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 0.375 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.375 mg - tablet, modified release - excipient ingredients: calcium hydrogen phosphate; hypromellose; magnesium stearate; silicon dioxide - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 0.75 mg modified release tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 0.75 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.75 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; calcium hydrogen phosphate; silicon dioxide - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 4.5 mg modified release tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 4.5 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 4.5 mg - tablet, modified release - excipient ingredients: silicon dioxide; magnesium stearate; hypromellose; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 2.25 mg modified release tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 2.25 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 2.25 mg - tablet, modified release - excipient ingredients: silicon dioxide; magnesium stearate; hypromellose; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.